Table 3 Cox proportional hazards model of baseline prognosticators for intrahepatic new recurrence-free survival in patients with early stage HCC after radiofrequency ablation.
Factors | Univariate | Multivariate | ||
|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | |
Age, per 1 year increase | 1.00 (0.97–1.02) | 0.858 | ||
Gender, male vs female | 1.10 (0.66–1.86) | 0.709 | ||
BMI, per kg/m2 increase | 1.17 (0.70–1.94) | 0.543 | ||
Diabetes mellitus, yes or no | 1.07 (0.64–1.78) | 0.786 | ||
ESRD, yes or no | 1.24 (0.45–3.44) | 0.675 | ||
CSPH, yes or no | 1.92 (0.92–3.98) | 0.081 | ||
Tumor number, solitary vs multiple | 0.72 (0.42–1.24) | 0.236 | ||
Tumor stage, I vs II | 1.30 (0.75–2.26) | 0.352 | ||
Tumor size, ≥ 3 cm vs < 3 cm | 1.38 (0.77–2.48) | 0.275 | ||
HBsAg positive, yes or no | 0.81 (0.45–1.48) | 0.502 | ||
NA before RFA, yes or no* | 1.62 (0.56–4.62) | 0.372 | ||
NA after RFA, yes or no* | 1.61 (0.51–5.14) | 0.421 | ||
Anti-HCV positive, yes or no | 1.09 (0.60–1.98) | 0.781 | ||
IFN before RFA, yes or no** | 1.01 (0.53–1.92) | 0.988 | ||
IFN or DAA after RFA, yes or no** | 0.42 (0.21–0.84) | 0.014 | ||
AFP(ng/ml), ≥200 vs <200 | 4.21 (1.71–10.40) | 0.002 | 4.34 (1.75–10.77) | 0.002 |
Child-Pugh class A vs B or C | 0.88 (0.49–1.58) | 0.662 | ||
Ascites, yes or no | 1.10 (0.54–2.24) | 0.804 | ||
NLR ≥ 2.5 vs <2.5 | 1.04 (0.60–1.78) | 0.898 | ||
PLR ≥ 100 vs <100 | 0.69 (0.38–1.24) | 0.215 | ||
PNI ≥ 40 vs <40 | 1.40 (0.60–1.78) | 0.231 | ||
ALBI grade, 1 vs 2/3 | 0.63 (0.36–1.12) | 0.116 | ||
FIB-4, per 1 increase | 1.02 (0.96–1.08) | 0.529 | ||
